1 Detailed pre-specified analysis from a sub study of SYNCHRONIZE-1 show that, relative to baseline, survodutide achieved a reduction of up to 34% in visceral fat, with the proportion of lean mass loss reflecting no more than 10.8% of change in total tissue mass at the highest dose, alongside an up to 63.1% reduction of liver fat, indicating a targeted reduction in metabolically harmful fat after 76 weeks
People without diabetes often experience slightly greater weight loss than those with type 2 diabetes
Glutathione helps flip the switch to turn them back into their active, useful forms
It is unlikely that GLP-1 agonists themselves are directly responsible for the acne that some patients may develop during treatment
McCoy AT, Benoist CC, et,al
DermaVue Face-Saver Protocol Month 1